EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The Effect of Losartan in Preventing Paclitaxel‐Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study

Aalaa Mahmoud Ahmed Shawqi Mahmoud, Emad Shash, Hayam Ateyya, Farida A Okasha, Nouran Omar El Said iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026

DOI: 10.1002/phar.70124 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Verfasst von Aalaa Mahmoud Ahmed Shawqi Mahmoud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt. Hauptthemen laut MEDLINE: Losartan, Paclitaxel, Peripheral Nervous System Diseases, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paclitaxel‐induced peripheral neuropathy (PIPN) is a condition that persists chronically in more than 60% of affected individuals, and currently there are no proven PIPN prophylaxis. Pre‐clinical data suggest the angiotensin‐II–receptor blocker losartan may attenuate neuro‐inflammation and nerve injury. This study was conducted to assess losartan's neuroprotective effect against PIPN in patients with breast cancer.

Methods

In this single‐center, open‐label, randomized, controlled trial, women with early‐stage breast cancer scheduled for weekly paclitaxel (80 mg/mg 2 or 12 doses) were enrolled and randomized 1:1 to losartan 100 mg once daily plus standard care or standard care alone. The primary end point was incidence of grade 2 or higher neuropathy, per National Cancer Institute Common Terminology Criteria of Adverse Events (NCI‐CTCAE v5.0). Secondary end points included time‐to‐neuropathy (in days), patient quality of life (QoL) assessed by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group‐Neurotoxicity (FACT/GOG‐NTX), pain intensity using visual‐analogue scale (VAS), serum nerve growth factor (NGF) levels, and safety.

Results

Between December 2023 and December 2024, 89 Patients Were Randomized (Losartan, n = 45; Control, n = 44). Losartan Significantly Reduced Grade ≥ 2 Neuropathy Incidence (33.3% vs. 86.4%, p < 0.001) and Delayed Its Onset (73.27 vs. 43.75 Days; Hazards Ratio [ HR ] = 0.2, 95% Confidence Interval [ CI ]: 0.11–0.35) Compared With Standard Care Alone, Respectively. At 12 Weeks, Patients Treated With Losartan Reported Superior QoL ( FACT / GOG ‐ NTX : 31.87 ± 6.43 vs. 15.45 ± 10.04; p < 0.001) and Reduced Pain Scores (Median VAS 3 vs. 8; p < 0.001) Compared With Standard Care Alone, Respectively. NGF Levels Were Comparable and Adverse Events Were Similar Between Groups.

Conclusions

Daily losartan reduced and delayed clinically significant paclitaxel‐induced neuropathy while improving patient‐reported outcomes, without additional toxicity. These findings support repurposing losartan as a low‐cost PIPN prophylactic and justify validation in larger, multicenter trials. Trial Registration ClinicalTrials.gov ( NCT06135493 )

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LosartanPaclitaxelPeripheral Nervous System DiseasesBreast NeoplasmsAntineoplastic Agents, PhytogenicAngiotensin II Type 1 Receptor BlockersNeuroprotective AgentsHumansFemaleMiddle AgedQuality of LifeAgedAdult

Stichwörter der Autor:innen

breast cancerlosartanneuroprotectivepaclitaxelperipheral neuropathypreventionquality of life

Substanzen

LosartanPaclitaxelAntineoplastic Agents, PhytogenicAngiotensin II Type 1 Receptor BlockersNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
  • Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University, Cairo, Egypt.

ORCID-Profile: Nouran Omar El Said

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Mahmoud, A. M. A. S., Shash, E., Ateyya, H., Okasha, F. A., & El Said, N. O. (2026). The Effect of Losartan in Preventing Paclitaxel‐Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70124

Vancouver

Mahmoud AMAS, Shash E, Ateyya H, Okasha FA, El Said NO. The Effect of Losartan in Preventing Paclitaxel‐Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70124

BibTeX
@article{Mahmoud2026,
  author = {Mahmoud, Aalaa Mahmoud Ahmed Shawqi and Shash, Emad and Ateyya, Hayam and Okasha, Farida A and El Said, Nouran Omar},
  title = {The Effect of Losartan in Preventing Paclitaxel‐Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  doi = {10.1002/phar.70124}
}
Kostenlos starten →